Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial

BACKGROUND: Patients with type 2 diabetes mellitus (T2DM) remain at increased cardiovascular residual risk and endothelial dysfunction, even after optimizing metabolic control and treatment by sodium-glucose-2 transporter inhibitors (SGLT2-is). The present study was based on the hypothesis that prop...

Descripción completa

Detalles Bibliográficos
Autores principales: Breder, Ikaro, Cunha Breder, Jessica, Bonilha, Isabella, Munhoz, Daniel B., Medorima, Sheila T. Kimura, Oliveira, Daniela C., do Carmo, Helison R., Moreira, Camila, Kontush, Anatol, Zimetti, Francesca, Zanotti, Ilaria, Carvalho, Luiz Sergio F., Nadruz, Wilson, Muscelli, Elza, Quinaglia, Thiago, Sposito, Andrei C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534094/
https://www.ncbi.nlm.nih.gov/pubmed/33062236
http://dx.doi.org/10.1177/2040622320959248

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534094/
https://www.ncbi.nlm.nih.gov/pubmed/33062236
http://dx.doi.org/10.1177/2040622320959248

Ejemplares similares